Effects of Dietary Conjugated Linoleic Acid in Advanced Experimental Polycystic Kidney Disease

Abstract

Background/Aims: Several dietary interventions, including those involving conjugated linoleic acid (CLA), slow progression of polycystic kidney disease (PKD) when initiated in the early stages of disease in Han:SPRD-cy rats. However, in humans, kidney disease is often undetected until extensive renal injury has developed. The objective of this study therefore was to determine whether initiating dietary CLA intervention in advanced PKD would slow disease progression. Methods: Adult male Han:SPRD-cy rats with advanced kidney disease were fed diets with or without 1% CLA for 16 weeks. Disease progression was assessed by serum urea, proteinuria, and creatinine clearance, and morphological and immunohistochemical measurements for pathologic change. Results: Renal injury was lower in the PKD rats given CLA compared to those given the control diet as indicated by a reduction in inflammation (42% less), fibrosis (28% less), oxidative damage (30% less) and proliferating cells (35% less). Diet had no effect on body, kidney, or liver weight, serum urea, serum creatinine, creatinine clearance, proteinuria, or cyst volume. Conclusions: Late dietary intervention with CLA reduced some disease-associated pathologies, but did not alter renal function in adult Han:SPRD-cy rats. The long-term anti-inflammatory, antioxidant, and antiproliferative benefits of CLA in advanced kidney disease remain to be determined.

Conjugated linoleic acid rat pretreatment reduces renal damage in ischemia/reperfusion injury: Unraveling antiapoptotic mechanisms and regulation of phosphorylated mammalian target of rapamycin

“…serum urea, serum creatinine, creatinine clearance, proteinuria, etc.) . More recently, in obese fa/fa Zucker rats with an advanced form of renal disease, Zhan et al.…”

“…serum urea, serum creatinine, creatinine clearance, proteinuria, etc.) [11]. More recently, in obese fa/fa Zucker rats with an advanced form of renal disease, Zhan et al confirmed that supplementation with c9,t11 CLA did not improve advanced obesity-associated nephropathy and t10,c12 CLA worsened the renal pathology in the final stages of the diseases [12].…”

“…Considering that CLAs show protective effects against the early stages of renal pathologies and that previous studies have shown the effects of CLAs on the signaling pathway mTOR , we hypothesized that dietary CLA prefeeding may offer novel opportunities for reducing the adverse outcomes of the renal IRI. Therefore, in the current study we investigated the effects of nutritional preconditioning with CLAs on renal function, oxidative stress, apoptotic cell death, and mTOR signaling in a rat model of renal IRI.…”

Trans-10,cis-12-conjugated linoleic acid worsens renal pathology and alters cyclooxygenase derived oxylipins in obesity-associated nephropathy

“…In autoimmune NZB/W F1 mice, CLA supplementation initiated with onset of renal failure was able to slow disease progression [17]. Dietary CLA supplementation in the Han:SPRD-cy model of polycystic kidney disease reduces renal inflammation, cell proliferation, fibrosis and oxidative damage [18][19][20]. In our previous studies in the obese fa/fa Zucker rat, 8-week supplementation of young rats with t10,c12 CLA alone or in combination with the c9,t11 isomer resulted in a reduction in glomerular hypertrophy [21], which is one of the earliest signs of OAN [22][23][24][25].…”